<DOC>
	<DOCNO>NCT00612716</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , cyclophosphamide busulfan , total-body irradiation donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell bone marrow umbilical cord blood may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving methotrexate cyclosporine transplant may stop happen . PURPOSE : This phase II trial study well donor stem cell transplant work treat patient previously treat lymphoma , multiple myeloma , chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Patients With Previously Treated Lymphoma , Multiple Myeloma , Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine allogeneic stem cell transplantation use unrelated match related haploidentical donor bone marrow unrelated match cord blood result timely , complete , durable engraftment patient previously treat lymphoma , multiple myeloma , chronic lymphocytic leukemia . - Determine incidence grade acute chronic graft-versus-host disease patient treat regimen . - Determine augment graft-versus-tumor effect accompany unrelated partially match donor allogeneic transplant reduces incidence relapse patient . OUTLINE : - Preparative regimen : Patients receive cyclophosphamide IV 2 hour day -7 -6 undergo total-body irradiation ( TBI ) twice daily day -4 -1 . Patients unable undergo TBI receive busulfan IV orally 4 time daily day -9 -6 cyclophosphamide IV 2 hour day -5 -2 . - Stem cell transplantation : All patient undergo unrelated match bone marrow umbilical cord blood transplantation partially match related allogeneic bone marrow transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive GVHD prophylaxis comprise methotrexate cyclosporine . Patients may enrol protocol direct towards GVHD prophylaxis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Donors &lt; 55 year age good health approve National Marrow Donor Program ( NMDP ) donor collection center . Related donor &lt; 70 year age . Recipients &lt; 55 year , satisfactory organ function ( exclude bone marrow ) Karnofsky activity assessment &gt; 90 % : Creatinine &lt; 2.0 mg/dl . Bilirubin , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2 x normal . Pulmonary function test Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; 50 % normal . Multi Gated Acquisition Scan ( MUGA ) &gt; 45 % injection fraction . Recipients unrelated donor match HLA A , B , DRBI locus , &lt; 35 year mismatch single HLA A B , DRBI locus . Umbilical cord blood ( 5 ) use unrelated stem cell source provide &gt; 2.0 x 10^7 cells/kg match 4 6 6 HLA A , B , DRBI locus . Cord blood graft may include single pair cord unit depend cell dose . Partially match related donor least haploidentical ( match &gt; 3 6 HLA A , B , DRB1 locus ) . Recipients fall one follow disease category Chronic lymphocytic leukemia must three : Rai Stage III/IV Progression previous Complete Response ( CR ) Partial Response ( PR ) include purine antagonist ( i.e . fludarabine ) . Recent chemotherapy responsiveness Advanced nonHodgkin 's lymphoma ( NHL ) . Lowgrade NHL ( Working Formulation A , B , C ) follow progression initial therapy asymptomatic diagnosis ( &gt; CR2 , &gt; PR2 ; response duration &lt; 1 year last therapy ) CR achieve ( &gt; PR1 ) . At least one prior therapy intermediate intensity ( e.g . CHOP ) . Mantle zone lymphoma progression follow initial therapy ( &gt; CR1 , &gt; PR1 ) . At least one prior therapy intermediate intensity ( e.g . CHOP ) . Intermediate grade lymphoma ( &gt; PR2 ) . Response duration &lt; 1 year prior therapy . Highgrade NonHodgkin 's Lymphoma ( NHL ) ( IWF H , I , J ) initial therapy &gt; stage III diagnosis ; progression even localize ( stage I , II ) diagnosis prior response duration &lt; 1 year . Recent chemotherapy responsiveness treatment &gt; 3 intermediate intensity regimen . Advanced Hodgkin 's disease beyond PR2 ( &gt; CR3 , &gt; PR3 ) . Recent chemotherapy responsiveness Multiple Myeloma ( &gt; CR2 , &gt; PR2 ) initial therapy prior PR . Recent chemotherapy responsiveness Recipients sign inform consent approve Committee Use Human Subjects University Minnesota . No available histocompatible relate donor ; 2nd bone marrow transplant ( BMT ) , HIV1 positive ; active uncontrolled infection ; resistant malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage II adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
</DOC>